key: cord-0829500-4omdxs3h authors: Qunaibi, E. A.; Helmy, M.; Basheti, I.; Sultan, I. title: A High Rate of COVID-19 Vaccine Hesitancy Among Arabs: Results of a Large-scale Survey date: 2021-03-10 journal: nan DOI: 10.1101/2021.03.09.21252764 sha: a073295e3769d7b2b4522de8bfd96ab01ffe1e1a doc_id: 829500 cord_uid: 4omdxs3h In this study, we present the results of the first large-scale multinational study (36,220 participants) that measures vaccine hesitancy among Arab-speaking subjects. Our analysis shows a significant rate of vaccine hesitancy among Arabs in and outside the Arab region (83% and 81%, respectively). The most cited reasons for hesitancy are concerns about side effects and distrust in healthcare policies, vaccine expedited production, published studies and vaccine producing companies. We also found that female participants, participants 30-59 year-old, those with no chronic diseases, those with lower-level of academic education, and those who do not know the type of vaccine authorized in their countries are more hesitant to receive COVID-19 vaccination. On the other hand, participants who regularly receive the influenza vaccine, health care workers, and those from countries with higher rates of COVID-19 infections showed more vaccination willingness. Interactive representation of our results is posted on our project website at https://mainapp.shinyapps.io/CVHAA. ( Supplementary Fig 1) . Yet, the Arab region is understudied, despite the geographical spread, the 75 number of residents, and the number of cases and deaths. So, a large-scale multinational study for 76 this area is necessary. 77 Our study aims to fill the gaps by investigating vaccine acceptance using a large-scale survey 78 targeting the relatively understudied Arab populations living in different countries around the 79 world following vaccine availability and administration. Secondly, to unveil the barriers leading to 80 vaccine hesitancy and their prevalence among the participants using an extensive updated list of 81 barriers against vaccine acceptance. Thirdly, the study compares the answers of the respondents 82 residing in and outside the Arab world to evaluate the effect of socioeconomic, cultural, health 83 policies and political differences on their reported attitudes and barriers to acceptance. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint The Survey of Arab COVID-19 Vaccine Acceptance (SACVA) is an open online survey that was 87 conducted using the online platform www.surveyplanet.com from 14-Jan 2021 to 29-Jan, 2021. 88 The sample population was a convenience sample targeted through a digital campaign using social The survey data was analyzed using R software-v.4.0.2. Descriptive statistics and analytical graphs 114 were used as needed. Participants were also subcategorized based on country of residence. Arab 115 countries with less than 100 participants (Somalia, Djibouti and Comoros) were grouped together 116 in one category and labeled "Other Arab countries". The non-Arab countries where the Arabic 117 speaking respondents were residing were classified into groups: European countries (n=30), North 118 American countries (n=3), Turkey and the rest of non-Arab countries as others (n=88). The 119 answers to the 14 th question, "Do you intend to take the vaccine?", were used as a dependent 120 variable and were analyzed using binary logistic regression. Two of the answer choices ("Yes", 121 "Depends on the type of vaccine") were used to define vaccine acceptance while the other three 122 ("No", "Not sure", "I will wait and see its effects on others" ) were labeled as "Vaccine Hesitancy". Responses to the question of the barriers to acceptance (Question 17) were compared for gender, 124 academic education and country of residence using Chi-Square. Our acquisition and analysis of the 125 results followed the guidelines of the CHERRIES checklist 22 . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 158 When asked about their willingness to receive COVID-19 vaccine if the option is available to them; 159 4,548 (12.6%) of the respondents answered "Yes"; 1,615 (4.5%), answered "Depends on the type 160 of vaccine"; 7,552 (20.9%) answered "I will wait and see its effects on others"; 7,856 (21.7%) 161 answered "I am not sure"; and 14,649 (40.4%) chose "No". The first two choices were considered 162 acceptance to receive a vaccine while the last three were labelled as vaccine hesitancy (Fig 1) . 163 Variations in responses were analyzed using different factors as covariates (Fig 2) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. There were 3,905 participants who chose acceptance but yet had one or more barrier(s) selected. Of the 29 barriers, the most common responses were "I am afraid side effects of the vaccine will (Fig 4) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint to whomever takes the vaccine (3.9%). When asked who needs the vaccine, responses were: 231 whomever-the vaccine was proven to be effective and safe as per clinical studies (35.4%), specific 232 categories of people need it, but they're not the majority (30.5%), I don't know (24.9%), and No 233 one needs it (9.2%) (Fig 5) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Respondents who did not know the vaccine type available to them showed increased hesitancy. This may be attributed to the fact that some Arab countries were first to approve the Sinopharm (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. about safety 5 . The three forms of distrust (in healthcare policies, in vaccine expedited production and in published 287 studies) were notably higher among respondents residing in the Arab countries than those living 288 outside the Arab world. The same applies to the belief that the vaccine has not been tested on a 289 large enough number of people, just tens or hundreds, which reflects less awareness of the vaccine 290 development process in the Arab countries and highlights the need to educate the general public 291 on the subject. Similarly, more residents of the Arab world believe that the vaccine is not necessary 292 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint anymore because most people in the participant's country "have already been infected" or because 293 the infection rate is decreasing. The infection rate is in fact decreasing (supplementary Fig 1, panel 294 A) but the public may need to be made aware that future outbreaks are still a possibility. With the high rate of distrust, any form of coercion to take the vaccine may have negative impacts. 296 Lazarus's et. al. large-scale study indicated that promoting voluntary acceptance is a better route 297 and that coercion should be avoided 6 . Similarly, a systematic review indicated that "mandates could 298 increase resistance" 5 . In our study, the majority of participants (59.5%) believed that vaccination of decreased efficacy of some vaccines 31,32 , this concern of efficacy is expected to increase among 306 the public. do not seem to reflect the true nature of hesitancy and whether or not it changes its nature over 318 time. In 2015, the World Health Organization (WHO) Strategic Advisory Group of Experts on 320 Immunization defined vaccine hesitancy as a 'delay in acceptance or refusal of vaccination despite 321 the availability of vaccination services' 33 . We, therefore, question considering those who intend to 322 take the vaccine after a prolonged time of availability as "Accepting" since this may interfere with 323 the targeted achievement of collective immunity. In the present study, 20.8% of the participants chose (I will wait and see its effects on others)- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint high-risk groups such as people with chronic diseases are well-represented (n=5,839) or even over-368 represented (HCW, n=5,708). Our sample size was not pre-planned but was rather arbitrary 369 reflecting a convenience sample. We believe that the large number of participants and the 370 consistency of results in different countries that were geographically close and similar 371 socioeconomically confirm the reliability of our survey. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.03.09.21252764 doi: medRxiv preprint Once we have it, will we use it? A European survey on 406 willingness to be vaccinated against COVID-19 The COVID-19 vaccines rush: participatory community engagement 409 matters more than ever COVID-19 vaccine hesitancy worldwide: a systematic review of vaccine 411 acceptance rates Author Flattening the Curve of 414 COVID-19 Vaccine Rejection-An International Overview Confidence and Receptivity for COVID-19 Vaccines: A 416 Rapid Systematic Review A global survey of potential acceptance of a COVID-19 vaccine COVID-19 vaccination intent is decreasing globally | Ipsos Trust in COVID vaccines is growing High Rates of COVID-19 Vaccine Hesitancy and Its Association with 426 Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines 427 Determinants of COVID-19 vaccine acceptance in 429 Saudi Arabia: A web-based national survey Beliefs and Barriers Associated with COVID-19 Vaccination Among the General Population in Saudi Arabia Knowledge, Perceptions, and Attitude of Egyptians Towards the 435 Novel Coronavirus Disease (COVID-19) Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from 438 Survey data for COVID-19 vaccine preference 440 analysis in the United Arab Emirates Arab nations first to approve Chinese COVID vaccine -despite lack of 442 public data Change of Willingness to Accept COVID-19 Vaccine and Reasons of 444 Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong 445 Repeated Cross-Sectional Surveys. Vaccines coronavirus vaccines is rising globally, survey suggests | Imperial News | 447 What Is Driving the Decline in People's Willingness to Take the COVID-19 Vaccine in the United States? Worldometer -real time world statistics An interactive web-based dashboard to track COVID-19 453 in real time Improving the quality of web surveys: The Checklist for Reporting Results 455 of Internet E-Surveys (CHERRIES) COVID-19 Data Hub Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of Vaccine hesitancy among Maltese healthcare workers 460 toward influenza and novel COVID-19 vaccination Factors Associated With US Adults' Likelihood of Accepting The French public's attitudes to a future COVID-19 vaccine: The 465 politicization of a public health issue Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-467 Sectional Study in Indonesia Intention to participate in a COVID-19 vaccine clinical trial and to get 469 vaccinated against COVID-19 in France during the pandemic Acceptability of Vaccination Against Healthcare Workers in the Democratic Republic of the Congo Pragmatic Obs Oxford-AstraZeneca COVID-19 vaccine efficacy Oxford Covid jab less effective against South African variant, study finds | World Vaccine hesitancy: Definition, scope and determinants national survey of potential acceptance of COVID-19 vaccines in 482 healthcare workers in Egypt